Sanofi Exceeds Q3 Earnings Estimates and Raises FY26 Financial Outlook
Sanofi reported strong third-quarter financial results, significantly outperforming both top-line and bottom-line analyst expectations. Non-GAAP earnings per share reached €3.55, exceeding estimates by €2.04, while revenue grew 16.2% year-over-year to reach €14.44 billion. The company's growth was heavily driven by its blockbuster drug Dupixent, which saw sales rise 34.8% to €5.7 billion. Additionally, new pharma launches contributed €1.4 billion in sales, a 31.4% increase fueled by products such as ALTUVIIIO, Ayvakit, and Rezurock. Following these results, Sanofi has raised its financial outlook for fiscal year 2026.
Tickers: $SNY
Topics: Dupixent performance earnings beat pharmaceutical sales revenue growth